vwhxr9e

Property	Value
?:abstract	BACKGROUND: Coronavirus disease-19 (COVID-19) pandemic caused delays in definitive treatment of patients with prostate cancer Beyond the immediate delay a backlog for future patients is expected Such delays can lead to disease progression OBJECTIVE: We aimed to develop guidance on criteria for prioritization for surgery and reconfiguring management pathways for non-metastatic stage of prostate cancer who opt for surgical treatment A second aim was to identify the infection prevention and control (IPC) measures to achieve low likelihood of COVID-19 hazard if radical prostatectomy was to be carried out during the outbreak and whilst the disease is endemic DESIGN, SETTING AND PARTICIPANTS: An accelerated consensus process and systematic review We conducted a systematic review of the evidence on COVID-19 and reviewed international guidance on prostate cancer These were presented to an international prostate cancer expert panel (n=34) through an online meeting The consensus process underwent three rounds of survey in total Additions to the second- and third-round surveys were formulated based on the answers and comments from the previous rounds OUTCOME MEASURES: Consensus opinion was defined as ≥80% agreement, which were used to reconfigure the prostate cancer pathways RESULTS: Evidence on the delayed management of patients with prostate cancer is scarce There was 100% agreement that prostate cancer pathways should be reconfigured and develop measures to prevent nosocomial COVID-19 for patients treated surgically Consensus was reached on prioritization criteria of patients for surgery and management pathways for those who have delayed treatment IPC measures to achieve a low likelihood of nosocomial COVID-19 were coined as \'COVID-19 cold sites\' CONCLUSION: Re-configuring management pathways for prostate cancer patients is recommended if significant delay (>3-6 months) in surgical management is unavoidable The mapped pathways provide guidance for such patients The IPC processes proposed provide a framework for providing radical prostatectomy within an environment with low COVID-19 risk during the outbreak or when the disease remains endemic The broader concepts could be adapted to other indications beyond prostate cancer surgery
is ?:annotates of	<https://research.tib.eu/covid-19/entity/1vwhxr9e_hasAnnotation_C0242656> <https://research.tib.eu/covid-19/entity/1vwhxr9e_hasAnnotation_C0343640> <https://research.tib.eu/covid-19/entity/1vwhxr9e_hasAnnotation_C0376358> <https://research.tib.eu/covid-19/entity/1vwhxr9e_hasAnnotation_C0745283>
?:creator	<https://research.tib.eu/covid-19/entity/Tandogdu%2C_Z.%3B_Collins%2C_J.%3B_Shaw%2C_G.%3B_Rohn%2C_J.%3B_Koves%2C_B.%3B_Sachdeva%2C_A.%3B_Ghazi%2C_A.%3B_Haese%2C_A.%3B_Mottrie%2C_A.%3B_Kumar%2C_A.%3B_Sivaraman%2C_A.%3B_Tewari%2C_A.%3B_Challacombe%2C_B.%3B_Rocco%2C_B.%3B_Giedelman%2C_C.%3B_Wagner%2C_C.%3B_Rogers%2C_C._G.%3B_Murphy%2C_D._G.%3B_Pushkar%2C_D.%3B_Ogaya-Pinies%2C_G.%3B_Porter%2C_J.%3B_Ramesh_Seetharam%2C_K.%3B_Graefen%2C_M.%3B_Orvieto%2C_M._A.%3B_Covas_Moschovas%2C_M.%3B_Schatloff%2C_O.%3B_Wiklund%2C_P.%3B_Coelho%2C_R.%3B_Valero%2C_R.%3B_de_Reijke%2C_T._M.%3B_Ahlering%2C_T.%3B_Rogers%2C_T.%3B_van_der_Poel%2C_H._G.%3B_Patel%2C_V.%3B_Artibani%2C_W.%3B_Wagenlehner%2C_F.%3B_Nathan%2C_S.%3B_Erik_Bjerklund_Johansens%2C_T.%3B_Hawkey%2C_P.%3B_Kelly%2C_J.>
?:journal	BJU_Int
?:license	unk
?:publication_isRelatedTo_Disease	<https://research.tib.eu/covid-19/entity/COVID-19>
?:source	WHO
?:title	Management of patients who opt for radical prostatectomy during the COVID-19 pandemic: An International Accelerated Consensus Statement
?:type	<https://research.tib.eu/covid-19/vocab/Publication>
?:who_covidence_id	#922472
?:year	2020

Property

Value

?:abstract

BACKGROUND: Coronavirus disease-19 (COVID-19) pandemic caused delays in definitive treatment of patients with prostate cancer Beyond the immediate delay a backlog for future patients is expected Such delays can lead to disease progression OBJECTIVE: We aimed to develop guidance on criteria for prioritization for surgery and reconfiguring management pathways for non-metastatic stage of prostate cancer who opt for surgical treatment A second aim was to identify the infection prevention and control (IPC) measures to achieve low likelihood of COVID-19 hazard if radical prostatectomy was to be carried out during the outbreak and whilst the disease is endemic DESIGN, SETTING AND PARTICIPANTS: An accelerated consensus process and systematic review We conducted a systematic review of the evidence on COVID-19 and reviewed international guidance on prostate cancer These were presented to an international prostate cancer expert panel (n=34) through an online meeting The consensus process underwent three rounds of survey in total Additions to the second- and third-round surveys were formulated based on the answers and comments from the previous rounds OUTCOME MEASURES: Consensus opinion was defined as ≥80% agreement, which were used to reconfigure the prostate cancer pathways RESULTS: Evidence on the delayed management of patients with prostate cancer is scarce There was 100% agreement that prostate cancer pathways should be reconfigured and develop measures to prevent nosocomial COVID-19 for patients treated surgically Consensus was reached on prioritization criteria of patients for surgery and management pathways for those who have delayed treatment IPC measures to achieve a low likelihood of nosocomial COVID-19 were coined as \'COVID-19 cold sites\' CONCLUSION: Re-configuring management pathways for prostate cancer patients is recommended if significant delay (>3-6 months) in surgical management is unavoidable The mapped pathways provide guidance for such patients The IPC processes proposed provide a framework for providing radical prostatectomy within an environment with low COVID-19 risk during the outbreak or when the disease remains endemic The broader concepts could be adapted to other indications beyond prostate cancer surgery

is ?:annotates of